drugset / Trial / NCT06046820
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
Timeline
- Start
- 2023-11-05
- Primary completion
- 2026-01
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INZ-701 | Protein / enzyme biologic | 2.4 mg/kg | Subcutaneous |
| Comparator | Calcitriol | Small molecule | — | — |